Search Results

ABM Therapeutics is pleased to announce today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the investigation of ABM-1310 for the treatment of Glioblastoma (GBM) patients carrying BRAF V600E mutation, following the Orphan Drug Designation for ABM-1310 to treat malignant gliomas including GBM received in July.

ABM Therapeutics, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed in its multicenter Phase I study of ABM-1310 in patients with relapsed and drug resistant primary malignant brain tumors in China. This is the second clinical study of ABM-1310 in China.

ABM Therapeutics (ABM) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310, a novel small molecule BRAF inhibitor developed by the company, for the treatment of patients with glioblastoma (GBM) bearing BRAF V600 mutation.

ABM Therapeutics today announced that the first patient was successfully dosed with ABM-168 in the United States.

ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, is thrilled to announce a US exclusive distribution partnership with Mercury Medical for non-government acute care facilities.

Arcade Therapeutics and University of Texas Austin’s Institute for Mental Health Research jointly announced the closing of a $3.8M grant from the National Institute for Mental Health (NIMH) to support clinical investigation and validation of ABM-02 as a game-based treatment for Major Depressive Disorder (MDD).

ABM Therapeutics announced that its IND application for ABM-1310, a new-generation BRAF inhibitor, has been approved by the National Medical Products Administration to conduct Phase 1 clinical trials in patients of advanced solid tumors with BRAF mutation in China.

ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, announced the U.S. Food and Drug Administration 510 clearance of the BiWaze® Clear System.

ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, announced today it has received CE marking for their BiWaze® Cough system in accordance with European Union’s Medical Device Regulation (MDR) 2017/745.

Efforts by the ACC, the AHA, the HFSA, the Heart Rhythm Society and The Society for Cardiovascular Angiography & Interventions to create a new, independent Board of Cardiovascular Medicine under the ABMS are closer to becoming a reality with the creation of a formal Board of Directors and the announcement by the ABMS Advisory Board on Specialty Board Development of an open comment period.